INSUBCONTINENT EXCLUSIVE:
of China following the outbreak of coronavirus will affect Indian pharma companies.
Though the majority of the pharmaceutical manufacturing
facilities in China are located far away from the coronavirus-affected sites, there has been a disruption in the supply chain due to the
increase in prices of essential active pharmaceutical ingredients (API).
However, ICRA said that the impact of production shutdowns and
But earlier this week the department of pharma imposed export restrictions on 12 drugs including a few antibiotics.
India imports nearly 70
per cent of APIs from China
The BSE Healthcare index closed in green on Thursday's trade.
Crisil, another rating agency, is predicting that with the weather getting
warmer over the next two months, the impact of the outbreak may subside in China by April 2020
In the worst case, the epidemic might well extend through the first quarter of FY21, intensifying the severity of the impact, Crisil warned
